EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application carbidopa and levodopa tablets USP, 10mg/100mg, 25mg/100mg, and 25mg/250mg. Aurobindo Pharma’s carbidopa and levodopa tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), SINEMET Tablets, manufactured by ORGANON.

Carbidopa and levodopa tablets are indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Carbidopa and levodopa tablets has an estimated market size of US $80.2 Million for the twelve months ending September 2022, as per IQVIA.